Fundraising Fox
Instil Bio
NASDAQ: TILUnicorn · $2.2BDallas, US · Founded 2018 · New York corporation · 51 employees on LinkedIn · 5 known investors
Find your way into Instil Bio
Sign up to see every warm intro you have to Instil Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Instil Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Instil Bio is a biotechnology company that identifies and acquires or licenses therapeutic candidates for development, with a strategic focus on securing additional novel drug candidates targeting diseases with significant unmet medical needs. The company previously pursued cell therapies including a folate receptor alpha-targeted tumor infiltrating lymphocyte therapy before discontinuing its former lead bispecific antibody program in early 2026.
Founders & leadership
Instil Bio was founded in 2018 by Bronson Crouch.
Board
Investors · 5
How we know: Curative Ventures's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Vivo Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$381.2M disclosed across 4 rounds · 2019–2020
▶$185.4MraisedFeb 2021 · 26 investors · BiotechnologyRule 506(b)
- Sandeep LaumasExecutive Officer
- Gwen BinderDirector
- Nimish ShahDirector
- Jack NielsenDirector
- Neil GibsonDirector
- Kent McGaughyDirector
- Bronson CrouchExecutive Officer, Director
- George MatchamDirector
- Offering amount
- $185.4M
- Amount sold
- $185.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
- Nimish ShahDirector
- Bronson CrouchExecutive Officer, Director
- Jack NielsenDirector
- Gwen BinderDirector
- Kent McGaughyDirector
- Neil GibsonDirector
- George MatchamDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$515.9KraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
- George MatchamDirector
- Gwen BinderDirector
- Jack NielsenDirector
- Bronson CrouchExecutive Officer, Director
- Neil GibsonDirector
- Nimish ShahDirector
- Kent McGaughyDirector
- Offering amount
- $515.9K
- Amount sold
- $515.9K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$170.2MraisedAug 2020 · 15 investors · BiotechnologyRule 506(b)
- Nimish ShahDirector
- Jack NielsenDirector
- Kent McGaughyDirector
- Neil GibsonDirector
- Gwen BinderDirector
- Bronson CrouchExecutive Officer, Director
- George MatchamDirector
- Offering amount
- $170.2M
- Amount sold
- $170.2M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
Companies working in the same space as Instil Bio.
Frequently asked questions
- What does Instil Bio do?
- Instil Bio is a biotechnology company that identifies and acquires or licenses therapeutic candidates for development, with a strategic focus on securing additional novel drug candidates targeting diseases with significant unmet medical needs. The company previously pursued cell therapies including a folate receptor alpha-targeted tumor infiltrating lymphocyte therapy before discontinuing its former lead bispecific antibody program in early 2026.
- Who founded Instil Bio?
- Instil Bio was founded by Bronson Crouch in 2018.
- Who are Instil Bio's investors?
- Instil Bio's investors include Curative Ventures, Vivo Capital, Wellington Management, CPMG, Venrock.
- How much funding has Instil Bio raised?
- Instil Bio has disclosed $381.2M raised across 4 rounds.
- Where is Instil Bio headquartered?
- Instil Bio is headquartered in Dallas, US.